Logo

Ceres Nanosciences

Ginkgo Bioworks, Ceres Nanosciences Partner on Pathogen Monitoring

The partners have already set up labs in the Middle East and Africa and plan to build wastewater testing capacity in countries where Ginkgo has pathogen monitoring programs.

Ceres Nanosciences Wins $1.4M in NIH RADx Funding for Additional Wastewater Epidemiology Centers

Ceres will identify and establish five new centers of excellence to join an existing network of 16 sites that was established with prior RADx funding.

New Products Posted to GenomeWeb: Nonacus, ZeptoMetrix, Ceres Nanosciences, More

New products and services posted to GenomeWeb for the week of Oct. 10, 2022.

In Brief This Week: Thermo Fisher Scientific, DNAnexus, Precipio, Delfi Diagnostics, Streck, More

News items for the week of Sept. 12, 2022.

NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance

The Manassas, Virginia-based firm will collaborate with researchers at Emory University to develop a system for the Atlanta metro area.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.